Log in to save to my catalogue

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in...

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5101790

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

About this item

Full title

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

Publisher

England: BioMed Central Ltd

Journal title

Breast cancer research : BCR, 2016-11, Vol.18 (1), p.110, Article 110

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Single nucleotide polymorphisms (SNPs) in the estrogen receptor 1 (ESR1) and cytochrome P450 19A1 (CYP19A1) genes have been associated with breast cancer risk, endocrine therapy response and side effects, mainly in postmenopausal women with early breast cancer. This analysis aimed to assess the association of selected germline CYP19A1 and ESR1 SNPs...

Alternative Titles

Full title

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5101790

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5101790

Other Identifiers

ISSN

1465-542X,1465-5411

E-ISSN

1465-542X

DOI

10.1186/s13058-016-0771-8

How to access this item